Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Imatinib and Everolimus in Synovial Sarcoma
NCT01281865Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Jan 2011
- Primary completion
- Oct 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of everolimus, imatinib in synovial sarcoma (SS), sponsored by National Cancer Institute. Started Jan 2011; status: completed.
02
Drugs
everolimusimatinib
03
Conditions
synovial sarcoma (SS)
Beyond the preview
Go deeper on NCT01281865.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01281865.